May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Palladium-103 Plaque Brachytherapy for Uveal Melanoma: 17 Years Experience
Author Affiliations & Notes
  • P. T. Finger
    The New York Eye Cancer Center, New York, New York
    The New York Eye and Ear Infirmary, New York, New York
  • S. Krishna
    The New York Eye Cancer Center, New York, New York
  • K. Chin
    The New York Eye Cancer Center, New York, New York
  • G. Duvall
    Theragenics Corporation, Buford, Georgia
  • Footnotes
    Commercial Relationships  P.T. Finger, None; S. Krishna, None; K. Chin, None; G. Duvall, E, E.
  • Footnotes
    Support  The EyeCare Foundation, Inc, New York City, New York, and Theragenics Corporation, Buford, Georgia.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 42. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. T. Finger, S. Krishna, K. Chin, G. Duvall; Palladium-103 Plaque Brachytherapy for Uveal Melanoma: 17 Years Experience. Invest. Ophthalmol. Vis. Sci. 2008;49(13):42. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate the long term safety and efficacy of palladium-103 plaque radiation therapy for uveal melanoma.


A retrospective review of the results of 384 consecutively treated patients was performed. Each was treated over 5-7 continuous days, to a mean apex dose of 71 Gy. They were evaluated for tumor and patient specific characteristics as well as local control, visual acuity and eye retention.


There were 233 tumors posterior to the equator, 27 equatorial and 122 anterior melanomas. By AJCC-UICC classification there were 69-T1, 293-T2, 17-T3 and 4-T4 melanomas. In 1990, we treated the first patient with palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma. Now, 17-years later, the maximum follow-up is 205 months (mean, 47 months). There have been 13 incidents of tumor regrowth for a 97% local radiation control rate. Only 3% have required secondary enucleation. Best corrected visual acuities are 20/200 or better in 76% (291/384). This may be due (in part) to laser and bevacizumab treatment to prevent and/or treat radiation optic neuropathy and maculopathy.


At The New York Eye Cancer Center, palladium-103 ophthalmic plaque brachytherapy has provided local control and eye retention rates equivalent to or superior than published alternative radiation methods. Our visual acuity outcomes are markedly superior (Table).  

Keywords: melanoma • uvea • radiation therapy 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.